

Table S1. Summary of all statistical analysis for the NIH test.

Figure	Analysis	Sex	Dependent variable	Factors	Statistical value
1A	2-way ANOVA	Male	Latency to eat	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,40)} = 0.07, p = 0.780$ ***Genotype: $F_{(1,40)} = 42.52, p = 0.001$ Drug × Genotype: $F_{(1,40)} = 1.69, p = 0.201$
1B	2-way ANOVA	Male	Pellet intake	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,40)} = 0.48, p = 0.490$ ***Genotype: $F_{(1,40)} = 49.48, p = 0.0001$ Drug × Genotype: $F_{(1,40)} = 0.31, p = 0.576$
1C	2-way ANOVA	Female	Latency to eat	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,32)} = 0.195, p = 0.662$ ***Genotype: $F_{(1,32)} = 12.10, p = 0.001$ Drug × Genotype: $F_{(1,32)} = 0.28, p = 0.600$
1D	2-way ANOVA	Female	Pellet intake	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,32)} = 0.07, p = 0.783$ ***Genotype: $F_{(1,32)} = 16.69, p = 0.0001$ Drug × Genotype: $F_{(1,32)} = 1.41, p = 0.244$
1E	2-way ANOVA	Male x Female	Latency to eat	Sex (male vs female) × Genotype (Wistar vs msP)	Sex: $F_{(1,35)} = 0.27, p = 0.601$ Genotype: $F_{(1,35)} = 34.65, p = 0.0001$ Sex × Genotype: $F_{(1,35)} = 0.96, p = 0.332$
1F	2-way ANOVA	Male x Female	Pellet intake	Sex (male vs female) × Genotype (Wistar vs msP)	[®] Sex: $F_{(1,35)} = 4.91, p = 0.048$ Genotype: $F_{(1,35)} = 10.91, p = 0.002$ Sex × Genotype: $F_{(1,35)} = 0.01, p = 0.90$

Note: Significant changes are reflected as * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$ or sex effects as [®] $p \leq 0.05$.

Table S2. Summary of all statistical analysis for the CLAMS test

Figure	Analysis	Sex	Dependent variable	Factors	Statistical value
2A	2-way ANOVA	Male	Average bout duration	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,27)} = 3.06, p = 0.092$ *Genotype: $F_{(1,27)} = 4.92, p = 0.035$ Drug × Genotype: $F_{(1,27)} = 1.10, p = 0.303$
2B	2-way ANOVA	Male	Total sleep time	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,27)} = 2.42, p = 0.131$ Genotype: $F_{(1,27)} = 0.51, p = 0.479$ Drug × Genotype: $F_{(1,27)} = 3.11, p = 0.089$
2C	2-way ANOVA	Male	Number of sleep bouts	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,27)} = 4.08, p = 0.053$ Genotype: $F_{(1,27)} = 4.13, p = 0.052$ Drug × Genotype: $F_{(1,27)} = 1.10, p = 0.210$
2D	2-way ANOVA	Female	Average bout duration	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,28)} = 1.21, p = 0.280$ Genotype: $F_{(1,28)} = 0.07, p = 0.789$ Drug × Genotype: $F_{(1,28)} = 2.49, p = 0.126$
2E	2-way ANOVA	Female	Total sleep time	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,28)} = 0.38, p = 0.539$ Genotype: $F_{(1,28)} = 2.23, p = 0.146$ Drug × Genotype: $F_{(1,28)} = 9.36, p = 0.005$
2F	2-way ANOVA	Female	Number of sleep bouts	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,28)} = 0.76, p = 0.388$ Genotype: $F_{(1,28)} = 0.02, p = 0.872$ Drug × Genotype: $F_{(1,28)} = 1.58, p = 0.219$
2G	2-way ANOVA	Male × Female	Average bout duration	Sex (male vs female) × Genotype (Wistar vs msP)	Sex: $F_{(1,27)} = 1.23, p = 0.276$ Genotype: $F_{(1,27)} = 5.70, p = 0.024$ Sex × Genotype: $F_{(1,27)} = 2.61, p = 0.117$
2H	2-way ANOVA	Male × Female	Total sleep time	Sex (male vs female) × Genotype (Wistar vs msP)	Sex: $F_{(1,27)} = 0.89, p = 0.354$ Genotype: $F_{(1,27)} = 4.24, p = 0.049$ Sex × Genotype: $F_{(1,27)} = 0.46, p = 0.502$
2I	2-way ANOVA	Male × Female	Number of sleep bouts	Sex (male vs female) × Genotype (Wistar vs msP)	Sex: $F_{(1,27)} = 0.003, p = 0.954$ Genotype: $F_{(1,27)} = 4.72, p = 0.039$ Sex × Genotype: $F_{(1,27)} = 1.11, p = 0.300$

Note: Significant changes are reflected as $*p \leq 0.05$.

Table S3. Summary of statistical analysis for the acoustic startle test

Figure	Analysis	Sex	Dependent variable	Factors	Statistical value
3A	2-way ANOVA	Male	120 dB T1	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,26)} = 1.60, p = 0.217$ Genotype: $F_{(1,26)} = 0.84, p = 0.366$ Drug × Genotype: $F_{(1,26)} = 0.68, p = 0.414$
3B	2-way ANOVA	Male	120 dB T2-6	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,26)} = 0.55, p = 0.463$ **Genotype: $F_{(1,26)} = 10.56, p = 0.003$ Drug × Genotype: $F_{(1,26)} = 0.98, p = 0.330$
3C	2-way ANOVA	Male	120 dB final block	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,26)} = 0.10, p = 0.751$ ***Genotype: $F_{(1,26)} = 14.51, p = 0.001$ Drug × Genotype: $F_{(1,26)} = 0.66, p = 0.424$
3D	2-way ANOVA	Male	Prepulse inhibition	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,26)} = 1.19, p = 0.284$ **Genotype: $F_{(1,26)} = 9.32, p = 0.005$ Drug × Genotype: $F_{(1,26)} = 1.24, p = 0.274$
3E	3-way ANOVA	Male	80-105 dB	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP) × Intensity (80-105db)	Intensity: $F_{(5,130)} = 70.82, p = 0.0001$ Drug × Intensity: $F_{(5,130)} = 1.08, p = 0.373$ Genotype × Intensity: $F_{(5,130)} = 9.25, p = 0.001$ Drug × Genotype × Intensity: $F_{(5,130)} = 0.57, p = 0.720$
3F	2-way ANOVA	Female	120 dB T1	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,28)} = 2.15, p = 0.153$ **Genotype: $F_{(1,28)} = 8.89, p = 0.006$ Drug × Genotype: $F_{(1,28)} = 0.23, p = 0.630$
3G	2-way ANOVA	Female	120 dB T2-6	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,28)} = 1.43, p = 0.241$ Genotype: $F_{(1,28)} = 4.13, p = 0.052$ Drug × Genotype: $F_{(1,28)} = 2.26, p = 0.143$
3H	2-way ANOVA	Female	120 dB final block	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,28)} = 0.54, p = 0.466$ *Genotype: $F_{(1,28)} = 5.37, p = 0.028$ Drug × Genotype: $F_{(1,28)} = 1.20, p = 0.282$
3I	2-way ANOVA	Female	Prepulse inhibition	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP)	Drug: $F_{(1,28)} = 0.75, p = 0.392$ *Genotype: $F_{(1,28)} = 7.14, p = 0.012$ Drug × Genotype: $F_{(1,28)} = 0.64, p = 0.428$
3J	3-way ANOVA	Female	80-105 dB	Drug (vehicle vs mifepristone) × Genotype (Wistar vs msP) × Intensity (80-105db)	Intensity: $F_{(5,140)} = 34.60, p = 0.0001$ Drug × Intensity: $F_{(5,140)} = 0.58, p = 0.711$ Genotype × Intensity: $F_{(5,140)} = 4.88, p = 0.026$ Drug × Genotype × Intensity: $F_{(5,140)} = 1.72, p = 0.198$

Note: Significant changes are reflected as * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

Table S4. Summary of statistical analysis for sex differences for the acoustic startle test

Figure	Analysis	Sex	Dependent variable	Factors	Statistical value
3K	2-way ANOVA	Male x Female	120 dB T1	Sex (male vs female) × Genotype (Wistar vs msP)	Sex: $F_{(1,26)} = 12.08, p = 0.002$ Genotype: $F_{(1,26)} = 6.09, p = 0.020$ Sex × Genotype: $F_{(1,26)} = 4.81, p = 0.037$
3L	2-way ANOVA	Male x Female	120 dB T2-6	Sex (male vs female) × Genotype (Wistar vs msP)	@@@Sex: $F_{(1,26)} = 18.14, p = 0.0001$ Genotype: $F_{(1,26)} = 2.15, p = 0.154$ Sex × Genotype: $F_{(1,26)} = 0.09, p = 0.761$
3M	2-way ANOVA	Male x Female	120 dB final block	Sex (male vs female) × Genotype (Wistar vs msP)	@@@Sex: $F_{(1,26)} = 18.20, p = 0.0001$ Genotype: $F_{(1,26)} = 11.15, p = 0.003$ Sex × Genotype: $F_{(1,26)} = 1.30, p = 0.264$
3N	2-way ANOVA	Male x Female	Prepulse inhibition	Sex (male vs female) × Genotype (Wistar vs msP)	@Sex: $F_{(1,26)} = 5.61, p = 0.025$ Genotype: $F_{(1,26)} = 8.79, p = 0.006$ Sex × Genotype: $F_{(1,26)} = 0.02, p = 0.889$
3O	3-way ANOVA	Male x Female	80-105 dB	Sex (male vs female) × Genotype (Wistar vs msP)	@@@Sex: $F_{(1,26)} = 20.02, p = 0.0001$ Intensity: $F_{(5,130)} = 53.99, p = 0.001$ Sex × Intensity: $F_{(5,130)} = 12.66, p = 0.0001$ Genotype × Intensity: $F_{(5,130)} = 3.36, p = 0.007$ Sex × Genotype × Intensity: $F_{(5,130)} = 0.51, p = 0.767$

Note: Significant changes are reflected as @ $p \leq 0.05$, @@ $p \leq 0.01$, @@@ $p \leq 0.001$.